Sign Up Today and Learn More About Precede Biosciences Stock
Invest in or calculate the value of your shares in Precede Biosciences or other pre-IPO companies through EquityZen's platform.
Precede Biosciences Stock
Precede Biosciences is a biotechnology company that provides a blood-based approach to reveal disease-defining transcriptional biology.
About Precede Biosciences Stock
Founded
2005
Headquarters
Boston, MA, US
Industries
Travel and Tourism, Manufacturing, Space
Precede Biosciences Press Mentions
Stay in the know about the latest news on Precede Biosciences
Precede Biosciences Secures $83.5M in Total Financing to Scale Next-Generation Precision Diagnostics Platform
globenewswire • Jan 13, 2026
Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer
globenewswire • Oct 18, 2025
Precede Biosciences Presents ASCO 2025 Data Highlighting the Ability of its Liquid Biopsy Platform to Reveal the Biology Underlying Response and Resistance to ADCs and Radiopharmaceuticals
biospace • Jun 02, 2025
Precede Biosciences Presents Data at AACR 2025 Demonstrating Ability to Resolve Gene Expression for Thousands of Tumor-Specific Genes from a Simple Blood Test
globenewswire • Apr 27, 2025
Precede Biosciences Presents Data at AACR 2025 Demonstrating Ability to Resolve Gene Expression for Thousands of Tumor-Specific Genes from a Simple Blood Test
morningstar • Apr 27, 2025
Precede Biosciences Management
Leadership team at Precede Biosciences
Co-Founder and CEO
Rehan Verjee
Board Member
Wouter Meuleman
Join now and verify your accreditation status to gain access to:
- Precede Biosciences Current Valuation
- Precede Biosciences Stock Price
- Precede Biosciences Management
- Available deals in Precede Biosciences and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Precede Biosciences Cap Table and Funding History by Share Class and Liquidity Preferences
- Precede Biosciences Revenue and Financials
- Precede Biosciences Highlights
- Precede Biosciences Business Model
- Precede Biosciences Risk Factors
- Precede Biosciences Research Report from SACRA Research
Trading Precede Biosciences Stock
How to invest in Precede Biosciences stock?
Accredited investors can buy pre-IPO stock in companies like Precede Biosciences through EquityZen funds. These investments are made available by existing Precede Biosciences shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Precede Biosciences stock?
Shareholders can sell their Precede Biosciences stock through EquityZen's private company marketplace. EquityZen's network includes over 420K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 51K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."